Pfizer Whistleblower Claims Drug Company Falsified Data in Covid Vaccine Trial - BMJ


When the Pharmaceuticals giant made claims about its Covid 19 vaccine being 97% effective, alarm bells went off in the heads of many sceptics. No vaccine in history has ever come even close to such a high number, and the idea that a new, and entirely unproved type of vaccine, for what was claimed to be a new virus, would score so highly seemed very suspicious. The vaccine was developed at unprecedented speed, just 263 days, and seemed to achieve levels of performance previously only dreamt of for a vaccine. Safety too appeared to be 100%, as no mention of risk or adverse effects was made. It was the most effective, safest vaccine ever, made in a fraction of the time of any other vaccine in history. It all seemed just too good to be true. The Covid vaccine was hailed as a great success, but in truth, that 97% figure was just a sales pitch dreamt up by marketing men to be parroted by complicit technocrats.


Mike Yeadon, former Pfizer executive, reported that there was "clear evidence of fraud" in the Covid study, as well as demonstrating how the 97% figure was an example of the classic three-card-trick pulled by pharmaceuticals companies when they want to push their products onto an unsuspecting public.


Now a Whistleblower who worked on the Covid trial confirms the fraud, malpractice and general deception that Pfizer performed in pursuit of their biggest ever payday: The BMJ has published the whistleblowers report which makes for some shocking reading and calls into question the reliability of the data generated by Pfizer’s vaccine trials. It’s based on dozens of documents, photos, audio recordings and emails supplied to the BMJ by a researcher at one of Pfizer’s sub-contractors involved in testing the Covid vaccine. We are reprinting it here:

In autumn 2020 Pfizer’s chairman and chief executive, Albert Bourla, released an open letter to the billions of people around the world who were investing their hopes in a safe and effective covid-19 vaccine to end the pandemic. “As I’ve said before, we are operating at the speed of science,” Bourla wrote, explaining to the public when they could expect a Pfizer vaccine to be authorised in the United States.


But, for researchers who were testing Pfizer’s vaccine at several sites in Texas during that autumn, speed may have come at the cost of data integrity and patient safety. A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson, emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day. Jackson has provided The BMJ with dozens of internal company documents, photos, audio recordings, and emails.

Poor laboratory management On its website Ventavia calls itself the largest privately owned clinical research company in Texas and lists many awards it has won for its contract work. But Jackson has told The BMJ that, during the two weeks she was employed at Ventavia in September 2020, she repeatedly informed her superiors of poor laboratory management, patient safety concerns, and data integrity issues. Jackson was a trained clinical trial auditor who previously held a director of operations position and came to Ventavia with more than 15 years’ experience in clinical research coordination and management. Exasperated that Ventavia was not dealing with the problems, Jackson documented several matters late one night, taking photos on her mobile phone. One photo, provided to The BMJ, showed needles discarded in a plastic biohazard bag instead of a sharps container box. Another showed vaccine packaging materials with trial participants’ identification numbers written on them left out in the open, potentially unblinding participants. Ventavia executives later questioned Jackson for taking the photos.

Early and inadvertent unblinding may have occurred on a far wider scale. According to the trial’s design, unblinded staff were responsible for preparing and administering the study drug (Pfizer’s vaccine or a placebo). This was to be done to preserve the blinding of trial participants and all other site staff, including the principal investigator. However, at Ventavia, Jackson told The BMJ that drug assignment confirmation printouts were being left in participants’ charts, accessible to blinded personnel. As a corrective action taken in September, two months into trial recruitment and with around 1000 participants already enrolled, quality assurance checklists were updated with instructions for staff to remove drug assignments from charts.

In a recording of a meeting in late September 2020 between Jackson and two directors a Ventavia executive can be heard explaining that the company wasn’t able to quantify the types and number of errors they were finding when examining the trial paperwork for quality control. “In my mind, it’s something new every day,” a Ventavia executive says. “We know that it’s significant.”